… Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused … ELISpot analysis. Additionally, rAAV gene therapy in these animals remained effective … lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being …

… or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies … Efficacy of OCU400 Novel Modifier Gene Therapy for Retinitis Pigmentosa Location: Exhibitor … , MD, Duke Center for Ophthalmic Genetics, Duke Pediatric Retina, Adult vitreo …

… BioSciences has announced that its gene therapy candidate, PCRX-201 (enekinragene inzadenovec … in relation to the treatment or procedure. PCRX-201’s design … ’s high-capacity adenovirus gene therapy vector platform. The therapy is administered directly …

… Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis … its autologous cell-based gene therapy for adults and pediatric … the wounds showed 50% or better healing. For … of its own topical gene therapy in dystrophic epidermolysis bullosa …

… (prademagene zamikeracel) gene-modified cellular sheets or pz-cel ZEVASKYN … fully integrated cell and gene therapy cGMP manufacturing facility … well as other words or expressions referencing future events … inspections from the FDA or other regulatory agencies, …

… SGT-003 is an investigational gene therapy containing a differentiated microdystrophin construct … ’s product candidates; replicate preliminary or interim data from early-stage … of such trials; obtain, maintain or protect intellectual property rights related …

… of the Ras pathway, or gene mutations in the epidermal … utility and usability. BMC Bioinformatics (22, 433). doi.org… that survive acute EGFRi therapy upregulate YAP. Given the … from acute EGFRi therapy could facilitate YAP nuclear …

… cell therapy clinical trial for patients with relapse or refractory … the American Society of Gene and Cell Therapy (ASGCT) 28th … in patients with relapsed or refractory multiple myeloma treated … platform redefines adoptive cell therapy, enabling single IV, …

… Liquid Biopsy Assay for Therapy” in the Journal of … for MSI status and gene coverage. The assay exhibits … or “would” or the negative of these words or other similar terms or … financing; future acquisitions, divestitures or investments; the potential adverse …

… -011, a recombinant collagen therapy, through IND-enabling studies. … very fragile and tear or blister at the slightest … Nova Anchora’s innovative protein therapy, designed to restore defective … an emphasis on advancing gene modifying technologies. www.cure …